impact view continu view fairli valu ev/std
ebitda vs analyt peer given double-digit revenu growth profil
expect even limit margin expans previous
estim mse bp averag increas vs bp prior
compani invest heavili hire addit salespeopl support futur
growth increas confid rais revenue compound-annual-growth-rate
vs prior roughli global technolog sale client
buy gb global busi sale servic yet gb client
buy servic suggest strong opportun cross-sel
remain ew follow result rais pt follow
model updat
recap view result solid revenu ebitda adj ep
beat prior estim gb compos roughli
legaci ceb busi legaci saw cv growth note
cv shift compani review
transact found cv belong make comp
easier second straight quarter acceler legaci
busi contribut growth manag aspir gb
solid double-digit top-lin growth believ product
commerci term sale capac increas quota bear salespeopl
y/i quarter like continu grow double-digit
time achiev level guidanc lower due complet
divestitur piec talent assess busi
busi educ servic unit state america
unless otherwis note metric base modelwar
base consensu methodolog
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
strong organ growth potenti price current level
strong organ growth potenti price current level
deriv averag sotp valu dcf
dcf includ wacc termin growth rate
salesperson product acceler drive contract valu growth adj
ebitda margin expans revenu adj ebitda cagr
adj ebitda margin expand
aggress sale forc expans drive top-lin growth limit margin
expans revenu adj ebitda cagr adj
ebitda margin continu stay around
revenu growth deceler competitor becom aggress ceb
busi grow much expect revenu adj ebitda grow
cagr adj ebitda margin contract
market leader technolog
acquisit ceb provid
opportun replic sale practic
acquisit bring risk drag top-lin
among fastest organ growth
potenti price current valuat
strong track record organ growth
grew organ c/c basi
highli recur revenu stream
revenu contractu recur
histori effect cross sell
consult event segment support
growth total contract valu
retent research client
earn particular focu growth
total contract valu progress around
improv growth ceb busi
technolog spend profession
risk achiev price
margin pressur rapid growth
sale forc may off-set expans
gross margin level due favor
shift revenu mix
competitor rang start-up
larg consult firm may abl gain
market share research
spend revenu
histor highli correl
cyclic leav expos busi
integr ceb acquisit result
lower top-lin growth thu multipl
exhibit statement flow
valuat methodolog risk
pt deriv averag sotp valu dcf
dcf includ wacc termin growth rate risk pt includ
margin pressur rapid growth sale forc may off-set expans
gross margin level due favor shift revenu mix
competitor rang start-up larg consult firm may abl steal
spend revenu histor highli correl
highli cyclic leav expos busi cycl risk
integr ceb acquisit result lower top-lin growth
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
